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Abstract 31	  
Inflammasomes are molecular complexes activated by infection and cellular stress, leading to 32	  
caspase-1 activation and subsequent IL-1β processing and cell death. The autoimmune NZB 33	  
mouse strain does not express NLRP3, a key inflammasome initiator mediating responses to a 34	  
wide variety of stimuli including endogenous danger signals, environmental irritants and a 35	  
range of bacterial, fungal and viral pathogens. We have previously identified an intronic point 36	  
mutation in the Nlrp3 gene from NZB mice that generates a splice acceptor site. This leads to 37	  
inclusion of a pseudoexon that introduces an early termination codon and is proposed to be 38	  
the cause of NLRP3 inflammasome deficiency in NZB cells. Here we have used exon 39	  
skipping antisense oligonucleotides (AON) to prevent aberrant splicing of Nlrp3 in NZB 40	  
macrophages and shown that this restores both NLRP3 protein expression and NLRP3 41	  
inflammasome activity. These results indicate that the single point mutation leading to 42	  
aberrant splicing is the sole cause of NLRP3 inflammasome deficiency in NZB macrophages. 43	  
The NZB mouse provides a novel model for addressing a splicing defect in macrophages and 44	  
could be used to further investigate AON design and delivery of AONs to macrophages in 45	  
vivo.  46	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Introduction 49	  
Inflammasomes are multiprotein complexes that are assembled in response to microbial and 50	  
endogenous danger signals and are responsible for activating caspase-1, leading to both 51	  
prointerleukin (IL)-1β and IL-18 processing and pyroptotic cell death.1,2,3 Inflammasomes 52	  
can also activate apoptotic cell death through caspase-8 activation.4 The best-studied 53	  
inflammasome is initiated by oligomerisation of the NLRP3 protein. Many external and host-54	  
derived danger signals activate the NLRP3 inflammasome, including a range of pathogens, 55	  
the bacterial ionophore nigericin, host-derived molecules such as extracellular ATP and 56	  
environmental irritants including silica and asbestos.5,6,7 57	  
 58	  
Recently we demonstrated that bone marrow derived macrophages (BMMs) from NZB mice 59	  
are deficient in both NLRP3 and AIM2 inflammasome responses.8 The NZB strain is a model 60	  
of autoimmune haemolytic anaemia and systemic lupus erythematosus and develops both 61	  
anti-erythrocyte and anti-nuclear antibodies.9,10 Inflammasome deficiencies could alter the 62	  
interaction of the host with both microflora and pathogens, promoting cytokine release 63	  
favouring the development of autoimmunity. 64	  
  65	  
We proposed that the NLRP3 inflammasome defect in NZB cells is due to a point mutation 66	  
found in an intron that creates a splice acceptor site.8 The resulting pseudoexon introduces a 67	  
premature stop codon producing a less stable truncated NLRP3 protein, and an almost 68	  
complete lack of NLRP3 protein expression.  Here exon skipping antisense oligonucleotides 69	  
(AON)11 targeting the pseudoexon restored both NLRP3 protein expression and NLRP3 70	  
inflammasome activity, demonstrating that this is the sole defect preventing NLRP3 71	  
inflammasome function in the NZB strain. 72	  
 73	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 74	  
Results 75	  
To test whether the incorporation of the pseudoexon in NZB Nlrp3 mRNA is the sole reason 76	  
for the profound NLRP3 deficiency, AONs were designed to target the pseudoexon (7b) and 77	  
prevent its inclusion during pre-mRNA splicing (Figure 1A). The AONs were targeted to the 78	  
splice acceptor site (AON38), splice donor site (AON40) and an intra-exonic region predicted 79	  
to contain several exonic splice enhancer motifs (AON39).12,13 80	  
 81	  
Preliminary experiments demonstrated that AON39, but not AON38 or AON40, was able to 82	  
substantially restore NLRP3 protein expression when electroporated into NZB BMMs (data 83	  
not shown). Subsequent experiments were conducted introducing AON39 or AON40 into 84	  
both NZB and C57BL/6 BMMs. After 4 h, cells were primed with LPS to up-regulate 85	  
NLRP3 expression. PCR of the region encompassing the pseudoexon from cDNA showed 86	  
that in the absence of AON treatment the NZB Nlrp3 mRNA was predominantly of the 87	  
longer form that includes the pseudoexon (Nlrp3')8 while C57BL/6 samples had the correctly 88	  
spliced form (Figure 1B). NZB cells treated with AON40 showed a small amount of correctly 89	  
spliced mRNA, whilst AON39 restored correct splicing to the majority of the Nlrp3 mRNA. 90	  
Quantitative western blotting showed restoration of LPS-induced NLRP3 protein levels in 91	  
NZB cells treated with AON39 to approximately 65% of the level in C57BL/6, while AON40 92	  
was largely ineffective (Figure 1C). Without LPS priming, a small amount of NLRP3 protein 93	  
was detected in NZB BMMs due to the action of AON39 on the smaller amount of nascent 94	  
Nlrp3 mRNA produced constitutively during this time. 95	  
 96	  
A panel of AONs were designed to microwalk around the annealing site of AON39 in an 97	  
attempt to further enhance exon skipping efficiency, with four overlapping AONs (AON80-98	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83) designed with slight target sequence and/or length variations (Figure 2A).  These were 99	  
introduced into NZB BMMs and changes in Nlrp3 expression were assessed using real time 100	  
PCR primers designed for either C57BL/6 Nlrp3 mRNA, or the NZB defective Nlrp3' 101	  
mRNA, previously validated on cloned cDNA templates. All four new AONs promoted 102	  
correct splicing, and AON83 was most efficient in suppressing the aberrant Nlrp3' transcript 103	  
and restoring the normal Nlrp3 transcript (Figure 2B).  Concomitantly, AON83 restored 104	  
NLRP3 protein levels in the NZB cells to almost 80% of that in C57BL/6 cells (Figure 2C).   105	  
 106	  
The longevity of the exon skipping effect of the AONs following electroporation was 107	  
investigated. AON83 and AON38 (effective and ineffective treatments respectively) were 108	  
electroporated into NZB and C57BL/6 BMMs. At 0, 4, 24 or 48 h post electroporation, cells 109	  
were primed for 4 h with LPS and then harvested for analysis by quantitative western blot 110	  
(Figure 3). Almost complete restoration of NLRP3 expression to C57BL/6 levels was 111	  
observed in NZB BMMs treated with AON83 and immediately primed with LPS, but overall 112	  
levels of induced NLRP3 expression in both strains were lower than later time points, 113	  
probably due to electroporation-associated stress. Effective NLRP3 restoration was observed 114	  
in cells left for 4 h before priming. Thereafter the effect of the AON declined with time but 115	  
was still observed 48 h post treatment. 116	  
 117	  
To test the effect of AON-mediated NLRP3 protein restoration on inflammasome-induced 118	  
pyroptotic cell death, cell viability was measured by MTT cleavage in response to the NLRP3 119	  
activator nigericin. A nigericin dose-dependent reduction in viability was seen in C57BL/6 120	  
cells (Figure 4A). Untreated and AON40-treated NZB cells showed a complete lack of 121	  
response but AON39 treatment restored the cell death response almost to the level of 122	  
C57BL/6. Subsequently, the effect of all AONs on the response to a single, high dose of 123	  
	   7	  
nigericin was tested. The resulting inflammasome function reflected the degree of NLRP3 124	  
protein restoration previously observed in cells, with AON83-treated cells the most sensitive 125	  
to nigericin, showing that AON treatment can restore NLRP3 inflammasome function in 126	  
NZB BMMs.  127	  
 128	  
Discussion 129	  
Here we have used splice switching AONs to show that aberrant splicing of the Nlrp3 gene 130	  
leading to inclusion of a pseudoexon is solely responsible for the lack of NLRP3 131	  
inflammasome response observed in macrophages from NZB mice. This provides proof-of-132	  
concept for restoring NLRP3 inflammasome function in NZB mice and analysing the effect 133	  
on progression and severity of autoimmune disease. In addition, NZB mice could be used as a 134	  
model to investigate in vivo delivery of AONs to macrophages.  135	  
 136	  
The AONs that targeted within the pseudoexon were effective while those targeting splice 137	  
acceptor and donor sites were not. Although targeting acceptor or donor sites has worked for 138	  
some genes,14,15 our results fit with a retrospective analysis of over 400 AONs designed for 139	  
the treatment of Duchenne muscular dystrophy, that showed exon-internal AONs to be the 140	  
most effective for some exons.16 Other work has suggested that the proximity of the AON 141	  
target site to the 5' end of the exon and the binding energetics of the oligonucleotide to the 142	  
RNA are correlated with effectiveness.17 Exonic splice enhancer sites promote splice site 143	  
recognition and are frequently targeted by effective AONs.18 Fine-tuning of the optimal AON 144	  
target sequences requires experimental validation; here this was achieved by microwalking 145	  
with overlapping AONs. The five overlapping exon-internal AONs had reproducible 146	  
differences in their effectiveness (Figure 2). Such differences could be due to thermodynamic 147	  
properties, secondary structure of the target sequence or the masking of additional exonic 148	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splice enhancers.  We had previously shown that longer AONs (25mers) could confer 149	  
substantial improvement in exon skipping efficiency, although this requires confirmation on a 150	  
case-by-case basis.19 151	  
 152	  
Apart from correction of a splicing defect, exon skipping AONs can be used experimentally 153	  
as an alternative to siRNA to knock down gene expression, or to induce specific splice 154	  
isoforms.20 A consideration for experimental use is the time course of effectiveness. Here we 155	  
showed that the AONs can work very quickly and must get to the nucleus, where they 156	  
hybridize with pre-mRNA,21 almost immediately.  157	  
 158	  
Of all disease-causing point mutations, 15% have been predicted to fall within splice sites 159	  
and it has been estimated that a further 25% of confirmed pathogenic nonsense or missense 160	  
mutations alter exonic splice enhancers and silencers and hence lead to abnormal splicing.22,23 161	  
Targeted exon skipping has potential therapeutic uses in knocking down the expression of 162	  
disease causing genes or splice variants and in the restoration of normal splicing if mutations 163	  
introduce deleterious pseudoexons.24 Exon skipping is currently being tested in clinical trials 164	  
for the treatment of Duchenne muscular dystrophy, where particular mutated exons of the 165	  
dystrophin gene can be targeted to restore a correct open reading frame and protein 166	  
expression.25,26 Challenges that remain for exon skipping AON therapy are to define the 167	  
optimal nucleic acid modifications required for stability, affinity and safety and also to 168	  
optimise delivery of AONs in vivo. The NZB mouse provides a model for a splicing defect in 169	  
macrophages, and could be used to investigate in vivo delivery of AONs to this compartment.  170	  
 171	  
2. Materials and methods 172	  
2.1 Materials 173	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Lipopolysaccharide (LPS) from Salmonella minnesota Re595 (Sigma Aldrich, St Louis, 174	  
USA) was dissolved in Dulbecco′s phosphate-buffered saline (PBS (Life Technologies, 175	  
Grand Island, USA))/0.1% triethylamine at 10 mg/ml. Nigericin (N7143 Sigma-Aldrich) was 176	  
dissolved in ethanol at 5 mM. Recombinant human CSF1 was a gift from Chiron, Emeryville, 177	  
CA. Complete RPMI 1640 is RPMI 1640 with 10% heat inactivated foetal calf serum (FCS), 178	  
1x GlutaMAX, 50 U/ml penicillin, 50 µg/ml streptomycin and 25 mM HEPES (all Life 179	  
Technologies). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (Life 180	  
Technologies) was prepared as a 5 mg/ml stock in PBS. 181	  
 182	  
2.2 Mice and Cell Culture 183	  
C57BL/6 and NZB mice were housed under specific pathogen-free conditions at the 184	  
University of Queensland and were used under approval from the University of Queensland 185	  
Animal Ethics Committee. Female mouse BMMs were differentiated as previously 186	  
described27 and used between day 7 and 10 of culture.  187	  
 188	  
2.8 Treatment of BMMs with exon skipping oligonucleotides  189	  
2'-O-methyl modified AONs with a full phosphorothioate backbone were synthesized on an 190	  
Expedite 8909 synthesizer using the 1micromole Thiol protocol, cleaved from the support, 191	  
desalted on NAP-10 columns and stored at -20˚C. AONs had the following sequences: 192	  
AON34- 5'AAUAGUUUUGGCAUCAAAAUUCU3'; AON38- 193	  
5'AUAUGGAAAUGUAUCUAGAUAAAUG3'; AON39- 194	  
5'CUAUGGGUUUUUGUGCUCCAAACUA3'; AON40-195	  
5'CUUACCCAAAAAGUUCUUGACUUAA3', AON80-196	  
5'GGUUUUUGUGCUCCAAACUA3', AON81-5'CUAUGGGUUUUUGUGGUCCA3', 197	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AON82-5'GGUUUUUGUGCUCCAAACUAUAAGU3', AON83-198	  
5'GGGUACUAUGGGUUUUUGUGCUCCA3'.  199	  
 200	  
BMMs were electroporated in 400 µl of complete RPMI-1640, with or without 3.5 µM AON 201	  
at 260 V, 1000 µF using a Bio-Rad Gene Pulser. Cells were immediately washed with 10 ml 202	  
of complete RPMI-1640 without FCS, pelleted (350 x g, 5 min), resuspended in complete 203	  
RPMI-1640 and plated out for analysis. Cells were plated for: RNA extraction at 4 million 204	  
cells/well in 6-well plates, protein at 250,000-500,000 cells/well in 24-well plates and 205	  
nigericin treatment/MTT assay at 70,000 cells/well in 96 well plates.  Plates were incubated 206	  
for 4 h and then primed with 100 ng/ml LPS for 4 h. 207	  
 208	  
2.9 Qualitative and Real Time-quantitative PCR of Nlrp3 variants.  209	  
RNA was extracted using the RNeasy mini-prep kit (Qiagen, Hilden, Germany). cDNA was 210	  
generated from each sample of RNA using oligo dT priming28 and amplified by conventional 211	  
PCR using the forward primer 2706 (5'AGAAACTGTGGTTGGTGAG3') and reverse primer 212	  
3125 (5'TGTGGTTGTGGGTCAGAA3'). The products were visualised after electrophoresis 213	  
on a 2% agarose gel.  Quantitative real time PCR was analysed by the ∆Ct method relative to 214	  
Hprt, as described previously.28 Primers used were NZBNlrp3-For 215	  
5'ATGCCTTGGGAGACTCAGGA3', NZBNlrp3-Rev 5'GCTGGTGGTGGGTACTATGG3', 216	  
C57Nlrp3-For 5'CAGAAGCTGGGGTTGGTGAAT3', C57Nlrp3-Rev 217	  
5'CTGAGTCCTGTGTCTCCAAGG3', Hprt-For 5'CAGTCCCAGCGTCGTGATTAG3' and 218	  
Hprt-Rev 5'AAACACTTTTTCCAAATCCTCGG3'. 219	  
 220	  
2.3 Nigericin Treatment and MTT assays 221	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Cells were treated with nigericin for 1 h. MTT assays of reductase activity indicating cell 222	  
viability29 were performed as previously described except that 5x MTT was added directly to 223	  
50 µL of medium that was left in the well and was not removed prior to addition of MTT 224	  
solubilisation solution (isopropanol/10% Triton X-100/0.1N HCl). Plates were left overnight 225	  
for maximum solubilisation of MTT formazan product prior to measurement of absorbance at 226	  
570 nm.  227	  
 228	  
2.6 Quantitative Western Blotting 229	  
Cell monolayers were lysed in 100 µl 66 mM Tris pH7.4, 2% SDS.  Samples were run on 15-230	  
well mini-PROTEAN TGX gels (Bio-Rad, Hercules, USA) and transferred to immobilon-FL 231	  
membrane (Millipore, Billerica, USA) using a mini-trans blot system (Bio-Rad) with Tris-232	  
Glycine transfer buffer containing 10% methanol. The membrane was washed for 15 min in 233	  
Tris-buffered saline (TBS) and then blocked for 1 h with Odyssey® Blocking Buffer (LI-234	  
COR, Lincoln, USA). Primary antibodies were diluted in the Odyssey® Blocking Buffer and 235	  
incubated overnight at 4°C. Primary antibodies used were anti-NLRP3/NALP3 mAB, Cryo-2 236	  
(#AG-20B-0014 Adipogen, San Diego, USA), anti-α-Tubulin (B-5-12, Sigma Aldrich) and 237	  
anti-GAPDH (#2275-PC-020, Trevigen, Gaithersburg, USA). Membranes were washed with 238	  
TBS containing 0.05% Tween-20 (TBS-T) and then incubated for 2 h, protected from light, at 239	  
room temperature in secondary antibody diluted in the LI-COR buffer/0.1% Tween-20/ 240	  
0.01% SDS. Secondary antibodies used were anti-rabbit (Dylight) 800 conjugate, anti-rabbit 241	  
(Dylight) 680 conjugate, anti-Mouse (Dylight) 800 conjugate and anti-mouse (Dylight) 680 242	  
conjugate (#5151P, #5366P, #5257 and #5470P respectively, Cell Signaling Technology, 243	  
Danvers, USA). Membranes were washed with TBS-T then TBS and scanned on the Odyssey 244	  
(LI-COR) and analysed with Image Studio Lite software (LI-COR).  245	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Figure Legends 372	  
Figure 1. Antisense oligonucleotide treatment can restore normal splicing and NLRP3 373	  
expression in NZB cells. (A) Diagram showing the Nlrp3 pseudoexon 7b, the location of the 374	  
point mutation (triangle) and the position of the AONs. AON38 anneals to the last 11bp 375	  
upstream of the pseudoexon and the first 14 bases of the pseudoexon. AON39 anneals 376	  
entirely within the pseudoexon targeting nucleotides 21 to 46 from the 5' end. AON40 377	  
anneals to the last 20 nucleotides of the pseudoexon and the first 5 nucleotides of the 378	  
downstream intron. (B) AON39 restores the normal Nlrp3 mRNA splicing within NZB 379	  
BMMs. BMMs from NZB and C57BL/6 mice were electroporated with AON39 or AON40 380	  
or with no addition, incubated for 4 h, then primed with 100 ng/ml LPS for 4 h. Conventional 381	  
PCR using primers in exons 6/7 and 9, flanking the pseudoexon 7b, shows the mRNA 382	  
variants with the pseudoexon (Nlrp3') or without the pseudoexon (Nlrp3) in NZB and 383	  
C57BL/6 BMMs after AON treatment. (C) AON39 restores NLRP3 protein levels in NZB 384	  
BMMs. Quantitative western blot of NLRP3 protein levels normalised to tubulin expression, 385	  
from cells treated as in panel B, with and without LPS priming. 386	  
Figure 2. Refinement of optimal AON targeting sequence.  (A) Diagram showing the 387	  
position of four additional AON relative to AON39. AON80, 81, 82 and 83 all anneal within 388	  
the pseudoexon, targeting nucleotides 21-40, 26-45, 16-40 and 26-50 from the 5' end 389	  
respectively. A predicted exonic splice enhancer motif is shown in white text. (B) Effects of 390	  
minor sequence changes to AON on Nlrp3 splicing, assessed by quantitative PCR. BMMs 391	  
from NZB or C57BL/6 mice were electroporated with either no addition (-), a control 392	  
oligonucleotide (cont), or an AON (38-40, 80-83), incubated for 4 h, then primed with 100 393	  
ng/ml LPS for 4 h. Quantitative real time PCR analysis was performed with primers specific 394	  
for Nlrp3' (with pseudoexon) and Nlrp3 (correct splicing). Data were normalised to NZB 395	  
without oligonucleotide for Nlrp3' results and C57BL/6 without oligonucleotide for Nlrp3 396	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results and show the mean and range from two experiments. (C) Effects of minor sequence 397	  
changes to AON on NLRP3 protein expression, assessed by quantitative western blotting. 398	  
NLRP3 protein levels from cells treated as in panel B were assessed relative to GAPDH 399	  
expression. Data shown is the mean and range of two experiments, normalised to the 400	  
C57BL/6 without AON sample.  401	  
Figure 3. Exon skipping AON have diminishing potency during the 48 h post 402	  
introduction into cells. BMMs from NZB and C57BL/6 mice were electroporated with no 403	  
addition (-), AON38 or AON83, plated and primed with 100 ng/ml LPS for 4 h, immediately 404	  
(0h) or after 4, 24 or 48 h of incubation. A quantitative western blot is shown for NLRP3 405	  
protein levels normalised to GAPDH. As samples within each experiment were analysed on 406	  
two separate blots, 0h and 4h sample data is shown relative to 4h C57BL/6 without 407	  
oligonucleotide and 24h and 48h sample data is shown relative to 48h C57BL/6 without 408	  
oligonucleotide. Quantitative data shown is the mean and range of two experiments.  409	  
Figure 4. Inhibition of aberrant splicing restores NLRP3 inflammasome function in 410	  
NZB BMMs. Relative cell viability was measured by MTT cleavage. (A) NZB and C57BL/6 411	  
BMMs were electroporated with nothing (-), AON40 or AON39, incubated for 4 h and then 412	  
primed with 100 ng/ml LPS for 4 h. NLRP3 inflammasome was triggered by treatment with 413	  
0, 1.25, 2.5, 5 or 10 µM nigericin for 1 h. Data represent the mean and standard deviation of 414	  
triplicate nigericin treatments of each AON-electroporated sample. Results are relative to the 415	  
mean of the 0 µM nigericin wells for each sample, and are representative of three 416	  
experiments performed. (B) NZB and C57BL/6 BMMs were electroporated with nothing (-), 417	  
control oligonucleotide (cont), or the indicated AON, incubated for 4 h and then primed with 418	  
100 ng/ml LPS for 4 h. Cells were then treated with or without 10 µM nigericin for 1 h. Cell 419	  
viability is shown relative to the unstimulated cells for each oligonucleotide treatment. Data 420	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is representative of two experiments and shows the mean and standard deviation of triplicate 421	  
treatments from one experiment.  422	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